Threshold halting enrollment in clinical trial

Redwood City biopharmaceutical firm Threshold Pharmaceuticals Inc. (THLD) will stop enrollment in a Phase 2 clinical trial evaluating the use of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The first stage of the trial, which included 21 patients, showed only one confirmed partial response. Under the design of the trial, three or more responses were required before an additional 29 patients would have been enrolled.

Patients already enrolled will be given the option to continue in the trial.

The Niners can win even when Jimmy Garoppolo has an off night

What we learned during crazy NFL weekend

Opinion: California’s misguided rooftop solar debate

Why aren’t we focused on the value of residential solar to reduce emissions?

S.F. extends program supporting workers recovering from COVID-19

San Francisco city officials announced Friday they will provide an additional $5.4 million to extend through June 2022 the local…